Related by context. All words. (Click for frequent words.) 71 Erythropoiesis Stimulating Agent 67 Erythropoiesis Stimulating Agents ESAs 66 Tumor Response 65 Estrogen Receptor 65 Demonstrates Efficacy 65 Secondary Hyperparathyroidism 65 Fondaparinux 65 erythropoiesis stimulating agent 64 Plaque Psoriasis 64 Ranolazine 64 See CLINICAL PHARMACOLOGY 64 Glucocorticoid 64 Shows Efficacy 64 Long Term Efficacy 64 Reduces Mortality 64 Improves Outcomes 63 Antitumor 63 Acute Ischemic Stroke 63 Shows Promise Against 63 Corticosteroid 63 Bosutinib 63 Clinical Efficacy 63 Cardiotoxicity 63 epoetin alpha 63 Clostridium difficile Infection 63 Patients Treated With 63 Drug Shows Promise 63 HCV Protease Inhibitor 63 Darbepoetin Alfa 62 ACE Inhibitors 62 Treating Chronic 62 Randomized Study 62 Demonstrates Potential 62 Psoriasis Drug 62 Dasatinib 62 Clinical Trial Evaluating 62 Initiates Clinical Trial 62 Laryngeal Cancer 62 Demonstrates Significant 62 Intravitreal 62 Clinical Outcome 62 Shows Statistically Significant 62 receptor tyrosine kinase inhibitor 62 Schizophrenia Treatment 62 Anticoagulation 62 Adjuvant Treatment 62 Anti Tumor 62 Drug Candidate 62 Diabetic Foot Ulcer 62 Tyrosine Kinase Inhibitor 62 Novel Oral 62 Rheumatoid Arthritis Patients 61 Granted Orphan Drug 61 Receives Marketing Authorization 61 Prolongs Survival 61 Myocardial Perfusion Imaging 61 Bevacizumab 61 Combo Therapy 61 Hemodialysis Patients 61 acadesine 61 Immunosuppressant 61 Demonstrates Positive 61 Pediatric Patients 61 Antiarrhythmic 61 Study Demonstrates 61 Anthracycline 61 Investigational Drug 61 R lenalidomide 61 Interferon beta 61 Renal Cancer 61 Bucindolol 61 Receives Orphan Drug Designation 61 Phase III Clinical Trial 60 Relapsing Multiple Sclerosis 60 Denufosol 60 Investigational Treatment 60 Chronic Heart Failure 60 RNAi Therapeutic 60 Anticoagulant 60 Carotid Endarterectomy 60 Treat Anemia 60 Antifungal 60 SUTENT ® 60 Novel Treatments 60 Initiates Clinical 60 Arterial Hypertension 60 Teva Provides Update 60 Antiplatelet 60 Cardiovascular Outcomes 60 Mimetics 60 PROCRIT R 60 antineoplastic 60 Appears Safe 60 Improves Survival 60 Allogeneic 60 sunitinib Sutent 60 Dry Powder Inhalers 60 Clinical Practice Guideline 60 JAK2 Inhibitor 60 Clinical Guideline 60 Coronary Angiography 60 Renal Function 60 Mycophenolate Mofetil 60 Myelodysplastic Syndromes 60 Immunosuppression 60 Guideline Update 60 Blinatumomab 60 Preclinical Data 60 Enzyme Replacement Therapy 60 Advanced Melanoma 60 Antihypertensive 60 Noxafil 60 Prospective Randomized 60 Novel Inhibitor 59 Antiepileptic Drug 59 fosbretabulin 59 FDA Approvals 59 Signaling Pathway 59 Autologous Stem Cell Transplantation 59 Granulocyte Colony Stimulating Factor 59 Pramlintide 59 Erythropoietic 59 pregabalin Lyrica 59 Antiviral Therapy 59 Clinical Trial Results 59 kidney urologic 59 Treatment Reduces 59 Levels Linked 59 Novel Therapeutic 59 thalidomide Thalomid 59 Novel Compound 59 metastatic neuroendocrine tumors 59 Anticonvulsant 59 Hsp# Inhibitor 59 Advanced Colorectal Cancer 59 pharmacodynamic parameters 59 Complicated Skin 59 Multicenter Study 59 Proves Effective 59 Pulmonary Arterial Hypertension 59 Immunomedics Announces 59 Osteoarthritis Patients 59 Hyperlipidemia 59 Carbamazepine 59 Hepatocellular Carcinoma 59 Microalbuminuria 59 Kidney Function 59 Anticancer Drug 59 Phase 2a Trial 59 Allergic Rhinitis 59 Septic Shock 59 Disease Modifying 59 Immunomodulatory 59 Skeletal Muscle 59 Phase 2b Clinical Trial 59 GW# [003] 59 Daptomycin 59 Orally Active 59 FDA Okays 59 HDAC Inhibitor 59 topically administered 59 Confirms Efficacy 59 Investigational Agent 59 Progenitor Cells 59 Novel Mechanism 59 Interferon Alfa 59 Peripheral Arterial 59 mycophenolate mofetil MMF 59 Therapeutic Targets 59 Fungal Infections 59 Controlled Study 59 Metabolic Disorder 59 Transdermal Delivery 59 Percutaneous Tibial Nerve Stimulation 59 RNAi Therapeutics 59 Myocardial Ischemia 59 Recombinant Human 59 Receives Orphan Drug 59 Pharmacodynamics 59 Omalizumab 59 Protein Expression 58 Subgroup Analysis 58 Growth Hormone Deficiency 58 Bone Metabolism 58 Adjunctive 58 Low Dose 58 Yondelis ® 58 Severe Asthma 58 Significantly Improved 58 Osteoporosis Treatment 58 allogeneic hematopoietic cell 58 immunomodulatory therapies 58 Medication Adherence 58 Biocompatibility 58 Submits NDA 58 Adjuvant Chemotherapy 58 Opioid Use 58 Pertuzumab 58 Cytotoxic 58 ergot derivatives 58 Anti Tumor Activity 58 Macrolide 58 Solid Tumors 58 polycythemia vera essential thrombocythemia 58 Cytochrome P# 58 Crit Rev 58 Kinase Inhibitors 58 Antipsychotic 58 Cinacalcet 58 Malignant Glioma 58 Holter Monitoring 58 Therapy Reduces 58 Synthetic Peptide 58 Risk Stratification 58 Demonstrates Sustained 58 Anti TNF 58 Antiviral Activity 58 Replacement Therapy 58 Adverse Event 58 Carotid Artery Stenting 58 Eculizumab 58 Meta Analysis 58 IMiDs ® compound 58 Certican 58 Renal Artery 58 ST Segment Elevation 58 TAXUS TM 58 Dialysis Outcomes 58 Adjuvant Therapy 58 Thyroid Hormone 58 Presents Preclinical Data 58 Left Ventricular Dysfunction 58 Lipid Lowering 58 Combination Treatment 58 Lymphoid 58 Protein Linked 58 C1 Inhibitor 58 Tyrosine Kinase Inhibitors 58 Refractory Angina 58 cisplatin gemcitabine 58 Small Molecule 58 Invasive Fungal Infections 58 Nicotine Vaccine 58 Hematological Malignancies 58 Transdermal Patch 58 Regimens 58 Pegylated Interferon 58 Study Reinforces 58 NDA Submission 58 Prognostic Value 58 Platinol ® cisplatin 58 Cardiometabolic 58 ATACAND 58 Study Shows Benefits 58 Inflammatory Arthritis 58 Controlled Trial 58 Randomized Controlled Trials 58 Parenteral Nutrition 58 Soft Tissue Sarcoma 58 Neuroprotection 58 Randomized Evaluation 58 Cyclosporin 58 Study Shows Promise 58 Multiple Myeloma Patients 58 Severe Sepsis 58 Trandolapril 58 Lambert Eaton Myasthenic 57 Clinical Practice Guidelines 57 Efficacy Trial 57 clevidipine 57 Receives Fast Track 57 Dalbavancin 57 Advanced Renal Cell 57 Phase Ib Clinical Trial 57 Chemotherapeutic Agents 57 Sleep Disturbances 57 Therapeutic Efficacy 57 Expanded Indication 57 Treatment Regimen 57 Metastatic Prostate Cancer 57 relapsing multiple sclerosis 57 Vertebral Fracture 57 Showed Significant 57 Small Vessel 57 Systemic Delivery 57 Pivotal Trial 57 Helicobacter pylori eradication 57 Venous Thrombosis 57 Generic Versions 57 Tesamorelin 57 Insulin Therapy 57 Liprotamase 57 patientswith 57 guanfacine extended release 57 Analytical Tool 57 Thrombotic 57 antiangiogenic agent 57 Unstable Angina 57 Pharmacologic 57 Orthostatic Hypotension 57 Comorbidities 57 Beta Blocker 57 vinca alkaloid 57 Trobalt 57 Initiates Enrollment 57 Prolongs Life 57 Stereotactic Body Radiation Therapy 57 Protease Inhibitors 57 Surgical Treatment 57 Hepatitis C Genotype 57 Tiotropium 57 Gentium Announces 57 human Chorionic Gonadotropin 57 Inflammatory Disease 57 Bare Metal Stent 57 Prostate Cancer Treatment 57 Immunotherapeutic 57 insulin glulisine 57 Hypertriglyceridemia 57 Stable Angina 57 Systemic Therapy 57 Therapeutic Antibodies 57 Cardiac Resynchronization 57 Nonclinical 57 Renal Cell Cancer 57 antithrombotic therapy 57 Paliperidone ER 57 Kinase Inhibitor 57 Ecallantide 57 Mouse Models 57 Analogs 57 Coronary Arteries 57 Prophylactic Treatment 57 Tacrolimus 57 Clinical Evaluation 57 Insulin Resistance 57 Randomized Trials 57 Improved Survival 57 Non Invasive Treatment 57 Myeloproliferative Neoplasms 57 Decompensated Heart Failure 57 Patient Registry 57 Phase IIIb study 57 Oxygen Saturation 57 Non inferiority 57 Radiofrequency Ablation 57 Acute Decompensated Heart Failure 57 Tumor Microenvironment 57 Superficial Femoral Artery 57 Polymorphisms 57 Aliskiren 57 Respiratory Virus 57 Confirmatory Phase 57 Protease Inhibitor 57 Febuxostat 57 Demonstrate Significant 57 alefacept 57 Approvable 57 Gastrointestinal Disorders 57 Isavuconazole 57 β blockers 57 Autoimmune Diseases 57 Polymerase Inhibitor 57 Hematological 57 Outcome Measures 57 Acute Myocardial Infarction 57 Appropriateness Criteria 57 Left Atrial 56 Evoltra ® 56 Test Detects 56 fludarabine cyclophosphamide 56 Vascular Wrap TM 56 Intrathecal 56 Patient Outcomes 56 ARIXTRA 56 Asthma Treatment 56 Hepatic 56 Pemphigus 56 Treatment Resistant 56 XIENCE V Everolimus Eluting 56 Bispectral Index 56 Photodynamic Therapy 56 Bone Metastases 56 Etanercept 56 Angiox ® 56 Lung Cancer Survival 56 Potent Inhibitor 56 Lung Cancer Drug 56 Anticancer Drugs 56 hypereosinophilic syndrome 56 ACOMPLIA R 56 Neuroendocrine Tumors 56 Technosphere ® 56 Iron Overload 56 Blood Pressure Monitoring 56 Taxane 56 Intraocular 56 Smooth Muscle 56 Retinal Vein Occlusion 56 Placebo Controlled Trial 56 Treatment Approaches 56 BiTE Antibody 56 Stent Thrombosis 56 Antibacterials 56 biostatistical analysis 56 HoFH 56 Interferon alpha 56 SPRIX ® 56 Lupus Drug 56 number NCT# ClinicalTrials.gov 56 Lowers Risk 56 Rilonacept 56 paclitaxel poliglumex 56 Diagnostic Criteria 56 Therapeutic Antibody 56 Inflammatory Markers 56 pain palliation 56 platelet aggregation inhibitors 56 Cytarabine 56 Metabolic Disease 56 Immunologic 56 Conjugate 56 Stakeholder Opinions 56 Bronchodilator 56 Ischaemic 56 Asthma COPD 56 Cutaneous T 56 Genes Linked 56 Rheumatoid Arthritis Drug 56 Kidney Disease Outcomes 56 Glucose Monitoring 56 Grants Orphan Drug 56 Circulatory Support 56 Inhibits 56 CD# CD# 56 Fluconazole 56 Begin Clinical Trials 56 ImmuKnow R 56 Left Ventricular 56 Adjuvant Breast Cancer 56 Atopic Dermatitis 56 Resurgex Plus R 56 Diagnostic Tests 56 Hazardous Drugs 56 Hematopoietic 56 Clin J 56 Prostacyclin 56 FDA Approves Drug 56 Guidelines Issued 56 CT Angiography 56 orally inhaled migraine 56 Subtypes 56 Cardiac Markers 56 Epilepsy Drug 56 Gene Variants 56 Acute Coronary Syndromes 56 Initiates Phase III 56 PEGylated interferon beta 1a 56 Pharmacogenomic 56 ICAEL 56 Randomized Double blind 56 Pharmacological 56 Dehydrogenase 56 Estrogen Therapy 56 Pressure Monitoring 56 Inhaled Nitric Oxide 56 Neupogen ® 56 ADVEXIN therapy 56 Phase 2a Clinical Trial 56 Migraine Treatment 56 Therapy Improves 56 Referenced EEG 56 IMiDs ® 56 Unresectable 56 Electrical Stimulation 56 mu opioid agonist analgesics 56 metastatic malignant 56 Bioequivalence 56 PROCRIT ® 56 Diuretic 56 Mitigation Strategies 56 null responder 56 Intravenous Formulation 56 Phase IIb Clinical Trial 56 Prognostic Factors 56 Practice Guideline 56 Anti VEGF 56 Expedited Review 56 Anti Infective 56 Nebulized Formoterol 56 Metastatic Colorectal Cancer 56 HIV HCV coinfected 56 Antisoma AS# 56 Lung Injury 56 histone deacetylase inhibitor 56 Venous Thromboembolism 56 Hospitalized Patients 56 Vertebral Fractures 56 rivastigmine Exelon 56 Cognitive Function 56 Phase IIa Clinical Trial 56 Prospective Multicenter 56 BCR ABL inhibitor 56 haematologic 56 please visit www.theESA.com 56 NeoRecormon 56 epoetin beta 56 ACCF AHA 56 Chronic Sinusitis 56 Minimally Invasive Treatment 56 IND Application 56 Helps Predict 56 Targeted Therapy 56 Antiangiogenic 56 Clolar ® 56 Seasonal Influenza Vaccine 56 Tumor Targeting 56 Immunogenicity 55 Postdoctoral Position 55 NSABP B 55 Drug Absorption 55 Primary endpoints 55 Fabry Disease 55 Localized Prostate Cancer 55 FDA Accepts 55 Hospital Acquired Pneumonia 55 Artificial Cornea 55 Demonstrates Statistically Significant 55 Myocardial Perfusion 55 Epitopes 55 essential thrombocythemia ET 55 targeted antifolate 55 Quantitation 55 Orphan Designation 55 Erectile Dysfunction Drug 55 Breast Tumor 55 Shown Effective 55 Percutaneous Coronary Interventions 55 thetreatment 55 Bisphosphonate 55 EFNS 55 Triapine R 55 Fibromyalgia Pain 55 Ischemic Stroke 55 alpha 2a 55 Paroxysmal 55 Investigational Device 55 Adverse Effects 55 Initiates Phase 2b 55 Pandemic Influenza Vaccines 55 Bioavailability 55 IL# PE#QQR 55 Rheumatoid Arthritis RA 55 Antithrombin 55 Beta Amyloid 55 Systemic Lupus Erythematosus SLE 55 prospective multicentre 55 Hematologic 55 Secretory 55 Improve Diagnosis 55 Therapeutic Vaccine 55 Phase 2b Trial 55 Cerebrospinal Fluid 55 Pathogen Detection 55 Rheumatoid 55 Biomarker Study 55 Anti Inflammatory 55 Squalamine 55 Anti Angiogenic 55 Cloretazine 55 Pivotal Phase II 55 sorafenib Nexavar 55 Breast Density 55 PKC# 55 Inhaled Steroids 55 Intravesical 55 ALN TTR 55 BrachySil ™ 55 Cannabinoid 55 Genes Involved 55 Randomized Clinical Trials 55 AIR2 Trial 55 Muscle Wasting 55 Cardiac Rhythm 55 Signaling Pathways 55 Glycosylation 55 Biological Therapy 55 BENICAR 55 Effectively Treats 55 Antiplatelet Therapy 55 ARCOXIA 55 Homeostasis 55 Acute Liver Failure 55 Antimalarial 55 Ultrasound Guided 55 Aryplase 55 Tocilizumab 55 Sentinel Lymph Node 55 Multiple Ascending Dose 55 Slows Progression 55 recurrent glioblastoma multiforme 55 Attenuates 55 Heterogeneity 55 Orphan Drugs 55 Hematological Cancers 55 subcutaneous immunoglobulin 55 Atypical Antipsychotic 55 Adenomas 55 Breast Cancer Treatment 55 Peritoneal Dialysis 55 CEQ# 55 Cardiac Marker 55 Immune Mediated 55 Mantle Cell Lymphoma 55 Present Preclinical Data 55 Lung Cancer Trial 55 von Willebrand Factor 55 Novel Therapies 55 Cytotoxicity 55 Fibromyalgia Syndrome 55 Early Diagnosis 55 relapsed MM 55 Receptor Agonist 55 Inhaled Liposomal Ciprofloxacin 55 Angiox R 55 Acute Stroke 55 Albuminuria 55 Assay Kits 55 Stem Cell Treatment 55 Environmentally Sensitive Areas 55 Amrubicin 55 Cancer Stem Cells 55 microtubule inhibitor 55 Breast Cancer Metastasis 55 Vulnerable Plaque 55 Stent Restenosis 55 nonstimulant 55 CRMD# 55 Acute Kidney 55 Main Outcome Measure 55 Platelet Function 55 Alemtuzumab 55 Post Operative 55 Late Breaker 55 Angiogenic 54 Coronary Revascularization 54 Further Validates 54 Lp PLA 2 54 Neurosurgical Products 54 Recommends Approval 54 Fast Track Status 54 Endothelial 54 Autoimmune Disease 54 familial amyloidotic polyneuropathy FAP 54 Inflammatory Diseases 54 Oxaliplatin 54 Abdominal Fat 54 chimeric monoclonal antibody 54 somatostatin analog 54 ORADUR ® 54 Systemic Sclerosis 54 CNS Disorders 54 PICSO ® 54 anti CD3 antibody 54 Zenvia Phase III 54 Cardiovascular Risk Factors 54 sirolimus eluting stents 54 Biologic Therapy 54 Surgical Procedures 54 Genetic Tests 54 Transplant Patients 54 Kahalalide F 54 treating neuropathic pain 54 Sustained Reduction 54 Anticancer 54 Anti infective 54 Psychiatric Disorders 54 Oncolytic Reovirus 54 orphan medicinal product 54 By JENNIFER LEARN 54 Radiation Induced 54 Apoptotic 54 histamine dihydrochloride 54 Chronic Lymphocytic Leukemia 54 Score TOS 54 Pathway Inhibitor 54 Proteasome 54 Prostate Cancer Vaccine 54 Tumor Cell 54 Oncolytic 54 percutaneous tibial nerve 54 Pivotal Phase III 54 Aurora Kinase 54 peripherally acting 54 Catena ® 54 Chemotherapeutic 54 sunitinib malate 54 Synaptic Plasticity 54 Myocardial 54 Valvular 54 TB Vaccine 54 Susceptibility Testing 54 Patient Enrollment 54 Treatment Outcome 54 preclinical efficacy 54 Clinical Outcomes 54 Recommended Practices 54 Simulect 54 Therapeutic Intervention 54 histone deacetylase HDAC inhibitor 54 Microwave Ablation System 54 Ocular Disease 54 Preclinical Models 54 TM Embolic Protection 54 Percutaneous Coronary Intervention 54 alpha GAL 54 Thrombolytic 54 Anti Inflammatory Drug 54 Female Urology 54 Panzem ® 54 Receives CE Marking 54 GRNCM1 54 Topical Treatment 54 Therapeutic Potential 54 demonstrated antitumor activity 54 Advanced Pancreatic Cancer 54 Nitazoxanide 54 Phase #b/#a clinical 54 Gastric Cancer 54 Myelodysplastic Syndrome 54 Antidepressant Drug 54 Quadrivalent 54 liposomal formulation 54 Spinal Disc 54 papillary renal cell carcinoma 54 Investigator Initiated 54 Depressive Symptoms 54 polyarticular 54 Systemic Juvenile Idiopathic 54 gefitinib Iressa 54 Wellstat 54 Infarct 54 Bendamustine 54 Capsules CII 54 Reyataz atazanavir 54 Anti Angiogenesis 54 Regenerative Cells 54 Diabetic Peripheral Neuropathy 54 Suicidality 54 Systolic Blood Pressure 54 Hormonal Contraceptives 54 erythropoietin receptor 54 Cimzia TM 54 Methylphenidate 54 HepaSphere 54 briakinumab 54 Preclinical Study 54 Valvular Heart Disease 54 Pharmacokinetic 54 Molecular Diagnostic 54 Endovascular Treatment 54 Efficacy Study 54 gemcitabine Gemzar ® 54 EVIZON TM 54 Clinical Relevance 54 Brain Stimulation 54 Antibiotic Use 54 Glaucoma Treatment 54 Diabetic Neuropathy 54 endothelin receptor antagonists 54 Biological Effects 54 Observational Study 54 Carbidopa 54 Orphan Drug status 54 Lamotrigine 54 Toxicogenomics 54 cardiovascular calcification 54 Diastolic Heart Failure 54 Carotid 54 Immune Therapy 54 Potent Antiviral Activity 54 Physiologic 54 HSCT 54 Allosteric 54 Tuberculosis Vaccine 54 glatiramer 54 Acute Coronary 54 Gout Drug 53 vismodegib 53 Receptor Signaling 53 Myelodysplastic Syndrome MDS 53 BCG refractory 53 Romidepsin 53 Multicentre 53 ATIR 53 Cancer Therapies 53 lymphoid malignancies 53 undergoing Percutaneous Coronary 53 Genetic Variation 53 Fluid Status 53 serotonin norepinephrine reuptake inhibitor 53 cetuximab Erbitux R 53 haematologic malignancies 53 Study Examines 53 CONBRIZA 53 ACEI 53 targeted radiotherapeutic 53 Dupuytren Disease 53 epithelial tumors 53 Sustained Efficacy 53 Aneurysm Repair 53 Pluripotent Stem Cells 53 Pharmacodynamic 53 Immune Cell 53 Phase 1b clinical trials 53 Bloodstream Infections 53 Atypical Antipsychotics 53 Transcriptional 53 Oligonucleotides 53 Improve Outcomes 53 Anti Platelet 53 PDUFA Date 53 allogeneic hematopoietic stem cell 53 Oral Compound 53 Patent Covering 53 MEDCAC 53 NK1 53 Heart Rate Variability 53 Renal Anemia 53 Uterine Cancer 53 Autoantibodies 53 Carfilzomib 53 Breast Exams 53 Safe Medication 53 Neuroprotective 53 Glycemic Control 53 Increases Risk 53 novel oral anticoagulant 53 Immunosuppressive 53 serotonin reuptake inhibitor 53 multiple myeloma MM 53 Val HeFT 53 Cognitive Impairment 53 neoadjuvant treatment 53 Insulin Delivery 53 Urinalysis 53 Study Validates 53 Carotid Revascularization Endarterectomy vs. 53 Adult Stem Cell Therapy 53 CCX# B 53 Proves Successful 53 FDA Orphan Drug 53 Long Term Outcomes 53 RhuDex 53 Febrile Neutropenia 53 Reductase 53 Perinatal Care 53 Ocrelizumab 53 depsipeptide 53 Etiology 53 Biosimilar 53 Preterm Birth 53 Hormone Replacement 53 Mesenchymal Stem Cells 53 Wound Therapy 53 Genetic Marker 53 Personalised Medicine 53 Solid Tumor 53 Targeted Therapies 53 Multicenter 53 SYN# 53 Renal Tumors 53 recurrent glioma 53 Immune Function 53 Non Responders 53 Intensive Care Medicine 53 Proliferative 53 Analytical Method 53 Cholinesterase Inhibitors 53 Schizophrenia Drug 53 Hepatitis C Infection 53 Protein Involved 53 factor TNF 53 PEG IFN 53 Cardiac Imaging 53 V Everolimus Eluting Coronary 53 Orphan Medicinal Product 53 CCX# 53 Angiographic 53 Hematopoietic Stem Cells 53 STEP BD 53 Antimicrobial Coating 53 Protein Biomarker 53 busulfan 53 neovascular age 53 Resubmission 53 Roche LightCycler ® 53 Velcade bortezomib 53 Menstrual Pain 53 Antiviral Agents 53 RECIST Response Evaluation Criteria 53 Minimally Invasive Spine Surgery 53 Solid Tumors criteria 53 Differential Diagnosis 53 multicenter clinical trials 53 Clofarabine 53 Acute Coronary Syndromes ACS 53 Total Knee Arthroplasty 53 iobenguane 53 CHAMPION PCI 53 immuno modulatory 53 Investigational Drugs 53 Systematic Review 53 liver resection surgeries 53 Functional Assessment 53 Islet Transplantation 53 EORTC NCI 53 Monoclonal Antibody 53 Nonsurgical 53 Diastat 53 Molecular Mechanism 53 antibiofilm 53 Vaccine Adjuvants 53 SSc 53 Positive Opinion 53 austriamicrosystems Introduces 53 FDA Panel Recommends 53 Antidiabetic 53 Cethrin R 53 Patients Suffering 53 Alternative Treatments 53 Intervention Trial 53 Blood Glucose 53 Anti angiogenic 53 anti infective treatments 53 Ridaforolimus 53 plus COPEGUS 53 Treating Depression 53 MabCampath 53 Inflammatory Bowel Diseases 53 Transcatheter 53 Sporanox 53 Gastrointestinal Tract 53 unstable angina UA 53 Authorized Generics 53 siRNA Delivery 53 Pivotal Trials 53 Gram Negative 53 Aggrenox ® 53 Chemotherapy Improves 53 Innate Immunity 52 Sutent sunitinib 52 Dry Powder Inhaler 52 pegylated interferon alfa 2b 52 Breast Carcinoma 52 Vascugel 52 Improve Patient Outcomes 52 Hepatocellular Carcinoma HCC 52 enzyme immunoassay EIA 52 Pharmacoeconomic 52 E1 INT TM 52 Orphan Status 52 Regains NASDAQ 52 reversing heparin 52 Cervical Dysplasia 52 pemetrexed Alimta 52 IgG1 monoclonal antibody 52 R vitespen 52 pharmacodynamic profiles 52 immunomodulatory agents 52 STEDESA 52 chronic myocardial ischemia 52 Endoluminal 52 Anti Diabetic 52 Phase Ib II 52 Cancer Vaccines 52 Natural Catastrophe Stress 52 DOR BioPharma Announces 52 Monoclonal Antibodies 52 Negative Symptoms 52 Pharmacogenetic 52 unstable angina pectoris 52 acute humoral rejection 52 Severe Primary IGFD 52 pharmacokinetic PK 52 orphan medicinal 52 phase IIIb 52 calculated creatinine clearance 52 Pregnancy Outcomes 52 glucocorticoid induced osteoporosis 52 associated vasculitis 52 PCWP 52 YONDELIS R 52 rxRNA 52 Doxil ® 52 Decompensated 52 Marketing Authorisation 52 evaluating tivozanib 52 diagnostic molecular imaging